Key Inclusion Criteria:
- Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the
lungs and the individual has progressed on standard of care therapy, cannot tolerate
standard of care therapy, refused standard of care therapy, or there is no standard of
care therapy.
- Age 18 years or older at the time of informed consent
- Life expectancy >12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Have at least one measurable lesion per RECIST v1.1 at Screening
Key Exclusion Criteria:
- Prior oncology therapy (chemotherapy, immunotherapy, biological therapy) or use of an
investigational agent or an investigational device within 21 days or 5 half-lives
before administration of first dose of KB707, whichever is shorter
- The subject is pregnant, nursing, or plans to become pregnant during study treatment
and through three months after the last dose of KB707
- Have known history of positive human immunodeficiency virus (HIV 1/2)